Moderna reports early success in respiratory infection vaccine
Moderna Inc.'s plans to create a vaccine to prevent two of the most common childhood viruses took a significant step forward Tuesday after the biotech disclosed the drug's success in an early clinical trial.
Moderna (Nasdaq: MRNA) is developing an array of vaccines using its messenger RNA science. The company hopes one of them, called MRNA-1653, could address two viruses that can cause pneumonia, croup and respiratory infections in children.
Early Phase 1 clinical trial data released Tuesday…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Allison DeAngelis Source Type: news
More News: Biotechnology | Children | Clinical Trials | Health Management | Pneomococcal Vaccine | Pneumonia | Respiratory Medicine | Science | Vaccines